Summary
From 1972–1983 53 patients underwent bone marrow transplantation. The median age was 18 years (3–41). 27 patients suffered from severe aplastic anaemia, 22 patients had acute leukaemia and 4 patients had chronic granulocytic leukaemia in chronic phase. Out of 22 patients with acute leukaemia, 2 had florid leukaemia, 2 had an early relapse and 18 patients were in first or second remission of their disease. 2/53 patients received a syngeneic transplant, 51/53 patients an allogeneic transplant. 47/51 patients had a HLA-A, B, C-identical, MLC-negative sibling donor, 1/51 had a HLA-A, B-C-identical, MLC-positive sibling donor, 2/51 a HLA-phaenotypical identical parental donor and 1/51 a HLA-identical, MLC-negative unrelated donor. The comparison of the results obtained in patients with severe aplastic anaemia transplanted from 1972–1979 with those transplanted from 1980–1983 shows that the bone marrow transplantation has to be performed in an early stage of the disease before the patients become multiple transfused, sensitized and severely infected and that the conditioning regimen for polytransfused patients has to be more intensive than in untransfused patients. From the patient group transplanted 1972–1979, only 1/14 patients is a long-term survivor in contrast to 8/13 patients transplanted from 1980–1983. 11/22 patients with acute leukaemia are alive between more than 5 years and 14 days after bone marrow transplantation. Only 1/4 patients, who were transplanted not in remission, is alive. For patients with acute leukaemia the bone marrow transplantation should be performed in an early stage of their disease when the tumor burden is small and when the patients are in good clinical condition. 2/4 patients with CGL are alive between 12 months and 3 months after bone marrow transplantation. In our patient group graft versus host disease was the most important problem with a high mortality due to GvHD associated infections.
Similar content being viewed by others
Abbreviations
- ALG:
-
Antilymphozyten-Globulin
- ALL:
-
akute lymphatische Leukämie
- AML:
-
akute myeloische Leukämie
- ATG:
-
Anti-T-Zell-Globulin
- AUL:
-
akute undifferenzierte Leukämie
- CML:
-
chronisch myeloische Leukämie
- CMV:
-
Cytomegalie
- GvHD:
-
Transplantat-gegen-Wirt-Reaktion
- KMT:
-
Knochenmarktransplantation
- MTX:
-
Methotrexat
- SAA:
-
schwere Panmyelopathie
- SD:
-
selektive Dekontamination
- TBI:
-
Ganzkörperbestrahlung
- TD:
-
totale Dekontamination
- TNI:
-
totale nodale Bestrahlung
Literatur
Arnold R, Schmeiser T, Heit W, Kohne E, Goldmann SF, Heimpel H, Kubanek B (1983) Treatment of severe acute gvhd with high dose ATG. Exp Hematol 11 (Suppl 13):21–23
Barrett AJ, Kendra JR, Lucas CF, Joss DV, Joshi R, Desai M, Hugh Jones K, Phillips RH, Rogers TR, Tabara Z, Williamson S (1982) Bone marrow transplantation for acute lymphoblastic leukaemia. Brit J Haematol 52:181–188
Deeg HJ, Storb R, Thomas ED, Kennedy MS, Flournoy N, Buckner CD, Clift R, Doney K, Sale G, Sanders J, Witherspoon R (1983) Marrow transplantation for acute nonlymphoblastic leukaemia in first remission: preliminary results of a randomized trial comparing cyclosporine and methotrexate for the prophylaxis of graft-versus-host-disease. Transplant Proc 15:1385–1388
Devergie A, Gluckman E (1982) Bone marrow transplantation in severe aplastic anaemia following cytoxan and thoracoabdominal irradiation. Exp Hematol 10 (Suppl 10):17–18
Filipovich AH, Quinones R, Vallera D, Kersey JH (1983) T-lymphocyte depletion of human bone marrow in vitro for prevention of graft versus host disease (GvHD) in allogeneic bone marrow transplantation (BMT). Exp Hematol 11 (Suppl 14):188 (abstract)
Friedrich W, Goldmann SF, Vetter U, Fliedner TM, Heymer B, Peter HH, Reisner Y, Kleihauer E (1984) Immunoreconstitution in infants with severe combined immunodeficiency following transplantation of HLA-haploidentical, T-cell depleted bone marrow. (Eingereicht zur Publikation)
Gale RP (1983) Bone marrow transplantation in leukaemia: recent advances and critical issues (Abstract). UCLA-Symposium on recent advances in bone marrow transplantation, Park City, Utah, 13–18 February
Gluckman E (1982) Report of the EGBMT party on severe aplastic anaemia. Exp Hematol 10 (Suppl 10):14–16
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18:295–304
Goldman JM, Bangham ASJ, McCarthy DM, Worsley AM, Hows JM, Gordon-Smith EC, Catovsky D, Batchelor JR, Goolden AWG, Galton DAG (1982) Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet II:623–625
Heimpel H, Frickhofen N, Heit W (1983) Aplastic anaemia: new trends in pathogenesis and treatment. In: Rozman C, Raides A (eds) ISH 7th Congress Barcelona. Main lectures, pp 69–88
Hickman RO, Buckner CD, Clift RA, Sanders JE, Stewart P, Thomas ED (1979) A modified right atrial catheter for access to the venous system in bone marrow transplant recipients. Surg Gynecol Obstet 148:871–875
Hoelzer D, Thiel E, Löffler H, Bodenstein H, Büchner T, Messerer D (for the German Multicentre ALL/AUL Study Group) (1983) Multicentre pilot study for therapy of acute lymphoblastic and acute undifferentiated leukemia in adults. Haematol. Blood Transf 28:36–40
Kurrle E, Bhaduri S, Krieger D, Pflieger H, Heimpel H (1983) Antimicrobial prophylaxis in acute leukaemia: prospective randomized study comparing two methods of selective decontamination. Klin Wochenschr 61:691–698
Ramsey NKC, Kim T, Nesbit ME, Krivit W, Coccia PF, Levitt SH, Woods WG, Kersey JH (1980) Total lymphoid irradiation and cyclophosphamide as preparation for bone marrow transplantation in severe aplastic anemia. Blood 55:344–346
Rodt H, Netzel B, Kolb H (1982) Suppression of GvHD antisera: clinical results in 20 patients. In: Baum SJ, Ledney GD, Thierfelder S (eds) Experimental Hematology Today. S Karger, Basel, pp 147–153
Schmeiser T, Arnold R, Kurrle E, Kubanek B, Pflieger H, Heimpel H, Krieger D (1983) Infection prophylaxis in bone marrow transplantation (BMT) with two different methods of gnotobiotic care. Exp Hematol 11 (Suppl 13):107–109
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED (1980) Chronic graft-versus-host syndrome in man: a clinicopathological study of 20 long-term Seattle patients. Am J Med 69:204–217
Storb R, Epstein RB, Graham TC, Thomas ED (1970) Methotrexate regimes for control of graft-versus-host disease in dogs with allogeneic marrow grafts. Transplantation 9:240–246
Storb R, Thomas ED, Buckner CD, Clift RA, Deeg HJ, Fefer A, Goodell BW, Sale GE, Sanders JE, Singer J, Stewart P, Weiden PL (1980) Marrow transplantation in thirty “untransfused” patients with severe aplastic anaemia. Ann Int Med 92:30–36
Storb R, Doney KC, Thomas ED, Appelbaum F, Buckner CD, Clift RA, Deeg HJ, Goodell BW, Hackman R, Hansen JA, Sanders J, Sullivan K, Weiden PL, Witherspoon RP (1982) Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anaemia patients. Blood 59:236–246
Storb R, Prentice RL, Buckner CD, Clift RA, Appelbaum F, Deeg J, Doney K, Hansen JA, Mason M, Sanders JE, Singer J, Sullivan KM, Witherspoon RP, Thomas ED (1983) Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 308:302–307
Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED (1981) Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 57:267–276
Sullivan KM, Parkman R (1983) Pathophysiology and treatment of graft-versus-host disease. In: Clinics in Haematology, Vol 12, No 3, Bone marrow transplantation, WB Saunders, London Philadelphia Toronto, pp 775–789
Thomas ED, Storb R (1970) Technique for human marrow grafting. Blood 36:507–515
Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Fluornoy N, Goodell BW, Hickman RO, Lerner KG, Neiman PE, Sale GE, Sanders JE, Singer J, Stevens M, Storb R, Weiden PL (1977) One hundred patients with acute leukemia treated by chemotherapy, total body irradiation and allogeneic marrow transplantation. Blood 49:511–533
Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson FL, Neiman PE, Sale GE, Sanders JE, Singer JW, Shulman H, Storb R, Weiden PL (1979a) Marrow transplantation for acute non-lymphoblastic leukemia in first remission. N Engl J Med 301:597–599
Thomas ED, Sanders JE, Fluornoy N, Johnson FL, Buckner CD, Clift RA, Fefer A, Goodell BW, Storb R, Weiden PL (1979b) Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood 54:468–476
Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD (1983) Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood 62:315–319
Author information
Authors and Affiliations
Additional information
Mit Unterstützung der Deutschen Forschungsgemeinschaft, SFB 112, Projekt H 5
Rights and permissions
About this article
Cite this article
Arnold, R., Schmeiser, T., Friedrich, W. et al. Knochenmarktransplantation bei Panmyelopathie, akuter Leukämie und chronisch myeloischer Leukämie: Ergebnisse der „Ulmer Transplantationsgruppe“. Klin Wochenschr 62, 577–585 (1984). https://doi.org/10.1007/BF01728176
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01728176